Identification of a circulating soluble form of CD80: Levels in patients with hematological malignancies

Leukemia and Lymphoma

Volumn 45, Issue 10, 2004, Pages 2111-2118

  Hock, Barry D ^a   Starling, G C ^b   Patton, W N ^a   Salm, N ^a   Bond, K ^a   McArthur, L T ^a   McKenzie, J L ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

CD86; CTLA 4; Leukemia; Soluble CD80

Indexed keywords

B7 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HEMOGLOBIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; BLOOD ANALYSIS; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VIVO STUDY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN PROTEIN INTERACTION; SOLUBILITY; THROMBOCYTE COUNT;

ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, DIFFERENTIATION; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCONJUGATES; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKEMIA, MYELOID; LYMPHOMA, MANTLE-CELL; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; SOLUBILITY;

EID: 4544269839     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190410001712199     Document Type: Article

References (43)

1. Guinan, E.C., Gribben, J.G., Boussiotis, V.A., Freeman, G.J. and Nadler, L.M. (1994) "Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity", Blood, 84, 3261-3282.
2. Sharpe, A.H. and Freeman, G.J. (2002) "The B7-CD28 superfamily", Nature Reviews in Immunology, 2, 116-126.
3. Wu, T.C., Huang, A.Y., Jaffee, E.M., Levitsky, H.I. and Pardoll, D.M. (1995) "A reassessment of the role of B7-1 expression in tumor rejection", Journal of Experimental Medicine, 182, 1415-1421.
4. Wilson, JL., Charo, J., Martin-Fontecha, A., Dellabona, P., Casorati, G., Chambers, B.J., et al. (1999) "NK cell triggering by the human costimulatory molecules CD80 and CD86", Journal of Immunology, 163, 4207-4212.
5. Suvas, S., Singh, V., Sahdev, S., Vohra, H. and Agrewala, J.N. (2002) "Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma", Journal of Biological Chemistry, 277, 7766-7775.
6. Hirokawa, M., Kuroki, J., Kitabayashi, A. and Miura, A.B. (1996) "Transmembrane signaling through CD80 (B7-1) induces growth arrest and cell spreading of human B lymphocytes accompanied by protein tyrosine phosphorylation", Immunology Letters, 50, 95-98.
7. Jeannin, P., Delneste, Y., Lecoanet-Henchoz, S., Gauchat, J.F., Ellis, J. and Bonnefoy, J.Y. (1997) "CD86 (B7-2) on human B cells. A functional role in proliferation and selective differentiation into IgE-and IgG4-producing cells", Journal of Biological Chemistry, 272, 15613-15619.
8. Azuma, M., Ito, D., Yagita, H., Okumura, K., Phillips, J.H., Lanier, L.L., et al. (1993) "B70 antigen is a second ligand for CTLA-4 and CD28", Nature, 366, 76-79.
9. Freeman, G.J., Gribben, J.G., Boussiotis, V.A., Ng, J.W., Restivo, V.A., Jr., Lombard, L.A., et al. (1993) "Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation", Science, 262, 909-911.
10. Freeman, G.J., Freedman, A.S., Segil, J.M., Lee, G., Whitman, J.F. and Nadler, L.M. (1989) "B7, a new member of the Ig superfarmly with unique expression on activated and neoplastic B cells", Journal of Immunology, 143, 2714-2722.
11. Sansom, D.M. (2000) "Review article: CD28, CTLA-4 and their ligands: who does what and to whom?", Immunology, 101, 169-177.
12. Collins, A.V., Brodie, D.W., Gilbert, R.J., Iaboni, A., Manso-Sancho, R., Walse, B., et al. (2002) "The interaction properties of costimulatory molecules revisited", Immunity, 17, 201-210.
13. Liebowitz, D.N., Lee, K.P. and June, C.H. (1998) "Costimulatory approaches to adoptive immunotherapy", Current Opinons in Oncology, 10, 533-541.
14. Abken, H., Hombach, A., Heuser, C., Kronfeld, K. and Seliger, B. (2002) "Tuning tumor-specific T-cell activation: a matter of costimulation?", Trends Immunol., 23, 240-245.
15. Zheng, Z., Takahashi, M., Aoki, S., Toba, K., Liu, A., Osman, Y., et al. (1998) "Expression patterns of costimulatory molecules on cells derived from human hematological malignancies", Journal of Experimental and Clinical Cancer Research, 17, 251-258.
16. Chaperot, L., Plumas, J., Jacob, M.C., Bost, F., Molens, J.P., Sotto, J.J., et al. (1999) "Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas", Experimental Hematology, 27, 479-488.
17. Trentin, L., Zambello, R.. Sancetta, R., Facco, M., Cerutti, A., Perin, A., et al. (1997) "B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules", Cancer Research, 57, 4940-4947.
18. Trentin, L., Perin, A., Siviero, M., Piazza, F., Facco, M., Gurrieri, C., et al. (2000) "B7 costimulatory molecules from malignant cells in patients with b-cell chronic lymphoproliferative disorders trigger t-cell proliferation", Cancer, 89, 1259-1268.
19. Brown, R.D., Pope, B., Yuen, E., Gibson, J. and Joshua, D.E. (1998) "The expression of T cell related costimulatory molecules in multiple myeloma", Leukemia and Lymphoma, 31, 379-384.
20. Maeda, A., Yamamoto, K., Yamashita, K., Asagoe, K., Nohgawa, M., Kita, K., et al. (1998) "The expression of co-stimulatory molecules and their relationship to the prognosis of human acute myeloid leukaemia: poor prognosis of B7-2-positive leukaemia", British Journal of Haematology, 102, 1257-1262.
21. Pope. B., Brown, R.D., Gibson, J., Yuen, E. and Joshua, D. (2000) "B7-2-positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy", Blood, 96, 1274-1279.
22. Faas, S.J., Giannoni, M.A., Mickle, A.P., Kiesecker, C.L., Reed, D.J., Wu, D., et al. (2000) "Primary structure and functional characterization of a soluble, alternatively spliced form of B7-1", Journal of Immunology, 164, 6340-6348.
23. Jeannin, P., Magistrelli, G., Aubry, J.P., Caron, G., Gauchat, J.F., Renno, T., et al. (2000) "Soluble CD86 is a costimulatory molecule for human T lymphocytes", Immunity, 13, 303-312.
24. Rennert, P., Furlong, K., Jellis, C., Greenfield, E., Freeman, G.J., Ueda, Y., et al. (1997) "The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion", International Immunology,, 9, 805-813.
25. Gerstmayer, B., Pessara, U. and Wels, W. (1997) "Construction and expression in the yeast Pichia pastoris of functionally active soluble forms of the human costimulatory molecules B7-1 and B7-2 and the B7 counter-receptor CTLA-4", FEBS Lett., 407, 63-68.
26. Runyon, K., Lee, K., Zuberek, K., Collins, M., Leonard, J.P. and Dunussi-Joannopoulos, K. (2001) "The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses", Blood, 97, 2420-2426.
27. Sturmhoefel, K., Lee, K., Gray, G.S., Thomas, J., Zollner, R., O'Toole, M., et al. (1999) "Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant", Cancer Research, 59, 4964-4972.
28. Flo, J., Tisminetzky, S. and Baralle, F. (2001) "Codelivery of DNA coding for the soluble form of CD86 results in the down-regulation of the immune response to DNA vaccines", Cellular Immunology, 209, 120-131.
29. Hock, B.D., Patton, W.N., Budhia, S., Mannari, D., Roberts, P. and McKenzie, J.L. (2002) "Human plasma contains a soluble form of CD86 which is present at elevated levels in some leukaemia patients", Leukemia, 16, 865-873.
30. Hock, B., McKenzie, J.L., Patton, W.N., Haring, L.F., Yang, Y., Shen, Y., et al. (2003) "The Clinical Significance of Soluble CD86 Levels in patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome", Cancer, 98, 1681-1688.
31. McHugh, R.S., Ratnoff, W.D., Gilmartin, R., Sell, K.W. and Selvaraj, P. (1998) "Detection of a soluble form of B7-1 (CD80) in synovial fluid from patients with arthritis using monoclonal antibodies against distinct epitopes of human B7-1", Clinical Immunology and Immunopathology, 87, 50-59.
32. Yang, S. and Sim, G.K. (1999) "New forms of dog CD80 and CD86 transcripts that encode secreted B7 molecules", Immunogenetics, 50, 349-353.
33. Yang, S., Sellins, K.S., Powell, T., Stoneman, E. and Sim, G.K. (2001) "Novel transcripts encoding secreted forms of feline CD80 and CD86 costimulatory molecules", Veternary Immunology and Immunopathology, 81, 15-21.
34. Ghia, P., Guida, G., Stella, S., Gottardi, D., Geuna, M., Strola, G., et al. (2003) "The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression", Blood, 101, 1262-1269.
35. Tarte, K., Zhang, X.G., Legouffe, E., Hertog, C., Mehtali, M., Rossi, J.F., et al. (1999) "Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells", Journal of Immunology,, 163, 514-524.
36. Costello, R.T., Mallet, F., Sainty, D., Maraninchi, D., Gastaut, J.A. and Olive, D. (1998) "Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition", European Journal of Immunology, 28, 90-103.
37. Heaney, M.L. and Golde, D.W. (1996) "Soluble cytokine receptors", Blood, 87, 847-857.
38. Werb, Z. and Yan, Y. (1998) "A cellular striptease act", Science, 282, 1279-1280.
39. The Non-Hodgkins Lymphoma Classification Project (1997) "A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma", Blood, 89, 3909-3918.
40. Rosenwald, A., Alizadeh, A.A., Widhopf, G., Simon, R., Davis, R.E., Yu, X., et al. (2001) "Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia", Journal of Experimental Medicine, 194, 1639-1647.
41. Oaks, M.K. and Hallett, K.M. (2000) "Cutting edge: A soluble form of CTLA-4 in patients with autoimmune thyroid disease", Journal of Immunology, 164, 5015-5018.
42. Magistrelli, G., Jeannin, P., Herbault, N., Benoit De Coignac, A., Gauchat, J.F., Bonnefoy, J.Y., et al. (1999) "A soluble form of CTLA-4 generated by alternative splicing is expressed by non-stimulated human T cells", European Journal of Immunology, 29, 3596-3602.
43. Magistrelli, G., Jeannin, P., Elson, G., Gauchat, J.F., Nguyen, T.N., Bonnefoy, J.Y., et al. (1999) "Identification of three alternatively spliced variants of human CD28 mRNA", Biochemical and Biophysical Research Communications, 259, 34-37.